MRC and MND Association award £3.9m to KCL and UCL for ALS/FTD research
Researchers aim to explore and investigate axonal dysfunction in neurodegeneration
Read More
Tag: amyotrophic lateral sclerosis
NeuroSense Therapeutics shares positive results of lead candidate in ALS
The neurodegenerative disease currently affects more than 200,000 people worldwide
Read More
UMC Utrecht and VectorY collaborate to identify biomarkers of ALS
The progressive neurological disorder currently affects more than 200,000 people worldwide
Read More
LifeArc and ALS TDI announce partnership to develop new clinical tools for ALS and MND
The project will validate two minimally invasive biomarkers for ALS: MMP-9 and TIMP-1
Read More
Francis Crick Institute and Broken String Biosciences partner for ALS research
The rare and fatal progressive neurodegenerative disease is estimated to affect 5,000 people in the UK
Read More
ALS Association partners with myTomorrows to improve clinical trial accessibility
The fatal motor neurone disease currently does not have a cure available to treat patients
Read More
Study reveals motor neuron region is affected in ALS
The neurological condition currently affects one in 300 people in the UK
Read More
Amylyx Pharma plans to file ALS therapy with the EMA this year
The previously-reported CENTAUR study of AMX0035 in 137 participants with ALS met its primary endpoint of slowing ALS progression
Read More
Experimental motor neurone disease therapy shows early promise
Phase I/II study results demonstrate proof-of-concept and proof-of-biology of tofersen
Read More
Mallinckrodt halts mid-stage Acthar trial citing pneumonia risk
ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and the spinal cord.
Read More
CHMP rejects AB Science’s ALS drug
AB Science’s share price has taken a hit after European Medicine Agency’s advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
Read More
Pfizer, Sangamo to work on gene therapies for ALS, FTLD
Pfizer and Sangamo Therapeutics are linking arms to develop a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
